Table of Contents

company-logo

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

C4 Therapeutics Dividend Announcement

• C4 Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on C4 Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

C4 Therapeutics Dividend History

C4 Therapeutics Dividend Yield

C4 Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing C4 Therapeutics stock? Use our calculator to estimate your expected dividend yield:

C4 Therapeutics Financial Ratios

P/E ratio-2.85
PEG ratio0.03
P/B ratio1.24
ROE-42.45%
Payout ratio0.00%
Current ratio6.31
Quick ratio6.31
Cash Ratio1.38

C4 Therapeutics Dividend FAQ

Does C4 Therapeutics stock pay dividends?
C4 Therapeutics does not currently pay dividends to its shareholders.
Has C4 Therapeutics ever paid a dividend?
No, C4 Therapeutics has no a history of paying dividends to its shareholders. C4 Therapeutics is not known for its dividend payments.
Why doesn't C4 Therapeutics pay dividends?
There are several potential reasons why C4 Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will C4 Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While C4 Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is C4 Therapeutics a dividend aristocrat?
C4 Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is C4 Therapeutics a dividend king?
C4 Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is C4 Therapeutics a dividend stock?
No, C4 Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy C4 Therapeutics stocks?
To buy C4 Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy C4 Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.